SUMMIT THERAPEUTICS INC (SMMT) Stock News
NASDAQ:SMMT - Nasdaq - US86627T1088 - Common Stock - Currency: USD
SMMT Latest News, Press Relases and Analysis
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Top stock movements in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report.
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.
Akeso survival data for ivonescimab misses expectations, STAT says
While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, Jonathan Wosen of STAT reports. In its submission to regulators, Akeso included data on patient survival, disclosing that an interim analysis following 157 patient deaths found that participants on ivonescimab had a roughly 22% reduced risk of death, with a hazard ratio of 0.784, a company spokesperson
4 Pipeline Stocks to Buy With $1,000 and Hold Forever
Pipeline companies remain well positioned despite the current disruption in the energy markets. At the same time, demand for natural gas is growing. This is coming from the increased power consumption stemming from artificial intelligence (AI), as well as from export demand from Mexico and for LNG (liquified natural gas) to Asia and Europe.
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Mentions: BNTX
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic
The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials.
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
Could Applied Digital Be the Best Under-The-Radar AI Stock?
The data center operator deserves a bit more attention.
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.
Why Summit Therapeutics Rocketed Double-Digits Today
Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET. Summit disclosed some preliminary results of its HARMONi-6 trial, conducted in partnership with Akeso. In the trial, Summit's antibody drug ivonescimab was administered along with platinum-based chemotherapy against the current standard of care, tislelizumab, which is made by BeiGene (NASDAQ: BGNE), in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug.
This Company's Co-CEOs Just Bought More Shares. Should You?
Nobody has more information about a company than its insiders, especially its executive management team. On April 8, Summit Therapeutics' co-CEOs, Robert Duggan and Maky Zanganeh, each exercised warrants, financial instruments that grant their holders the right (but not the obligation) to acquire a company's shares at a predetermined price before a particular date. Do Summit Therapeutics' prospects -- beyond this recent development -- justify investing in the stock today?
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill
Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts “limited reaction” in Pfizer’s shares following the news, JPMorgan tells investors that the decision is “mostly a positive” for Structure and Viking, both developing drugs in the
Why Summit Therapeutics Inc. (SMMT) Soared Last Week?
We recently published a list of 10 Firms Defy Market Slump, Record Double-Digit Gains Last Week. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other firms that defied the market slump and recorded double-digit gains last week. The stock market may have taken a beating […]
Mentions: OXY
3 Magnificent Stocks That Could Double or More by 2030
Three Motley Fool contributors think they've identified magnificent stocks that could double or more by 2030. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX) as stocks worth buying now. Prosper Junior Bakiny (CRISPR Therapeutics): Despite creating Casgevy, the first CRISPR-based gene-editing medicine to earn regulatory approval, CRISPR Therapeutics has not performed well in the past year and a half since hitting that milestone.
3 Magnificent Stocks That Could Double or More by 2030
Stock Market Crash: Is Palantir a Buy?
Palantir Technologies (NASDAQ: PLTR) has not been spared from the recent stock market crash, with the stock trading down roughly 29% from its highs as of this writing. One of the ongoing oddities about Palantir is that most investors don't know what the company actually does. Since then, it has developed an artificial intelligence (AI) platform that is meant to be used as an (AI) operating system where users can connect digital assets with their real-world counterparts to apply AI to real-world problems.
1 Stock to Buy Hand Over Fist in the Tariff-Induced Market Downturn
Buying through market drawdowns is the right thing to do.
Why XPeng Inc. (XPEV) Surged On Friday?
We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are going to take a look at where XPeng Inc. (NYSE:XPEV) stands against other Friday’s top performing stocks. The stock market finished the trading week on a positive note, wiping out earlier losses on Friday, as […]
Why Kingsoft Cloud Holdings Limited (KC) Surged On Friday?
We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are going to take a look at where Kingsoft Cloud Holdings Limited (NASDAQ:KC) stands against other Friday’s top performing stocks. The stock market finished the trading week on a positive note, wiping out earlier losses on Friday, […]